Biohaven's BHV-7000 Fails to Meet Primary Endpoint in Depression Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Clinical Trial Results: Biohaven's BHV-7000 failed to meet its primary endpoint in a Phase 2 trial for major depressive disorder, although favorable trends were observed in certain subgroups of more severely depressed patients, indicating potential value in specific populations.
- Safety Assessment: The drug was found to be generally safe and well-tolerated, with adverse events primarily mild to moderate, and incidences of headache and nausea at 10.7% and 4.2% respectively, demonstrating BHV-7000's tolerability advantage.
- Strategic Shift: Despite the subgroup analyses providing hypothesis-generating insights, Biohaven has opted not to pursue additional psychiatric clinical trials, focusing resources instead on key priority areas such as immunology, obesity, and epilepsy.
- Future Plans: Biohaven intends to present extensive updates on its clinical programs at the J.P. Morgan Healthcare Conference in January 2026, reflecting the company's ongoing commitment to its innovative therapeutic portfolio.
BHVN
$10.81+Infinity%1D
Analyst Views on BHVN
Wall Street analysts forecast BHVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN is 16.82 USD with a low forecast of 9.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 10.500
Low
9.00
Averages
16.82
High
30.00
Current: 10.500
Low
9.00
Averages
16.82
High
30.00
About BHVN
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
